GLP-1 Medicines and Eating-Disorder History: Screening Before Treatment

A weight-management intake form may ask whether you have ever had an eating disorder. That question deserves more than a quick checkbox. Past diagnoses, current behaviors and the supports that protect recovery can all affect what a safe plan needs to include.

You do not have to decide alone whether a symptom “counts” as an eating disorder before mentioning it. Explain what is happening, what has helped in the past and what worries you about appetite changes. The purpose of screening should be to understand your care needs, not to reward the person who gives the fewest complicated answers.

What the clinical advisory recommends

A 2025 advisory from four professional societies recommends referral to obesity-medicine and eating-disorder specialists for people with an eating-disorder history considering GLP-1s. It describes restrictive eating disorder as a general contraindication to use and recommends screening for several types of eating disorders¹.

This is clinical guidance, not a statement that the Wegovy label lists every eating-disorder diagnosis as a formal contraindication. Its labeled contraindications are a separate matter³. Neither distinction gives a website enough information to decide whether treatment is appropriate for an individual reader.

Ask the clinician how your history changes the assessment. If the service cannot provide that assessment, ask how referral works before committing to a medication subscription. A prescription pathway that cannot accommodate relevant history may not offer the support you need.

Less appetite is not the same as recovery

The National Eating Disorders Association describes concerns about missed meals, medication misuse and worsening eating-disorder thoughts or behaviors in susceptible people². An appetite change can look desirable in advertising while creating difficulties for someone working to maintain regular eating.

A helpful question is: “How will we distinguish an intended medication effect from a pattern that puts my recovery at risk?” Discuss how the team will hear about changes in eating and distress, not just whether weight is decreasing. A dashboard showing weight change cannot make that distinction on its own.

This also applies to people who have not received a formal diagnosis. Tell the clinician about recurrent restriction, purging, loss-of-control eating or anxiety about eating. Ask how that information is assessed rather than relying on a brief online eligibility result.

Do GLP-1s treat binge eating disorder?

Evidence of reduced appetite should not be presented as proof of eating-disorder treatment. In a small 17-week randomized pilot of liraglutide, 27 participants were analyzed. The reduction in binge episodes did not differ significantly from placebo; the study also had important medication-allocation and sample-size limitations⁴.

That trial does not establish semaglutide or tirzepatide as a treatment for binge eating disorder. Nor does a person's account of feeling less “food noise” answer questions about longer-term recovery, nutrition or recurrence. A promising research question and an established treatment recommendation are different things.

If you are seeking help for binge eating, make that the explicit reason for the appointment. Ask what established eating-disorder care is available and whether a proposed medication addresses another diagnosis. Do not let a weight-management enrollment process silently replace the care you intended to seek.

What to bring to an assessment

Bring any previous diagnoses, relevant treatment summaries and the contact details of clinicians currently involved in your care. Describe what recovery looks like for you and which approaches have been unhelpful. You can ask for a private conversation rather than trying to fit sensitive details into a general customer-support message.

Useful questions include whether weight discussions are necessary at every visit, how nutrition will be assessed and whether your existing therapist or dietitian can participate. Ask how records are shared and who coordinates the plan. Obtain consent-based arrangements rather than assuming everyone can already see the same notes.

Agree on monitoring that goes beyond the scale

Ask the team to explain which changes should prompt contact and how quickly messages are answered. Discuss eating patterns, physical symptoms and the thoughts or behaviors that matter in your particular recovery. The nutrition advisory emphasizes assessment and ongoing nutrition support during GLP-1 care¹.

The protein and nutrition guide covers general questions, but fixed calorie or protein targets from an article are not an individualized recovery plan. If tracking food or weight is distressing, tell your treating team so they can discuss an appropriate way to monitor care.

Our mood and anxiety guide addresses a related issue. Do not assume that a change in one regulatory warning resolves every psychological or nutritional concern. The follow-up plan should respond to your circumstances and the symptoms you actually report.

Separate side-effect support from recovery support

Nausea and vomiting are recognized Wegovy adverse reactions³. If they affect your ability to eat or drink, tell the prescriber rather than treating inability to eat as a sign that treatment is working particularly well. Ask how medical symptoms and recovery concerns will be considered together.

You should know how to obtain urgent medical care when symptoms are severe, and how to reach the usual team for emerging concerns. Do not wait for a scheduled weight check if you are becoming physically unwell. The monitoring guide explains why a normal baseline test does not replace later assessment.

Compare care arrangements before buying a plan

Once an appropriate clinical assessment has taken place, ask prospective programs about continuity, nutrition appointments, outside referrals and fees for additional visits. Clarify whether coaching means general education or care from someone with the expertise your history requires. Those services should not be assumed equivalent.

The Found review describes published coaching and program terms, and the Ro review explains another service model. These reviews do not establish eating-disorder expertise or endorse either program for this situation. The comparison workspace helps organize service questions; your treating clinicians should determine what level of care is appropriate before price becomes the deciding factor.